**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 35702**

**Manuscript type: ORIGINAL ARTICLE**

***Retrospective Study***

**Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients**

Lew D *et al.* Associations with reactions from TNF inhibitors

Daniel Lew, Soon Man Yoon, Xiaofei Yan, Lori Robbins, Talin Haritunians, Zhenqiu Liu, Dalin Li, Dermot PB McGovern

**Daniel Lew**, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

**Soon Man Yoon, Xiaofei Yan, Talin Haritunians, Zhenqiu Liu, Dalin Li, Dermot PB McGovern,** F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

**Lori Robbins,** Department of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

**ORCID number:** Daniel Lew (0000-0001-8843-6447); Soon Man Yoon (0000-0003-3885-6763); Xiaofei Yan (0000-0001-9825-1956); Lori Robbins (0000-0003-3149-8895); Talin Haritunians (0000-0002-9005-7750); Zhenqiu Liu (0000-0003-1535-4322); Dalin Li (0000-0003-4738-0074); Dermot PB McGovern (0000-0001-5621-759X).

**Author contributions:** Lew D collected and analyzed the data, and drafted the manuscript; Yoon SM and Robbins L helped collect the data and edit the manuscript; Yan X and Li D helped with the technical and statistical analysis; Liu Z and Haritunians T helped analyze the data and edit the manuscript; McGovern DPB designed and supervised the study, and revised the manuscript for important intellectual content; all authors have read and approved the final version to be published.

**Institutional review board statement:** The study was reviewed and approved by the Cedars-Sinai Institutional Review Board (IRB #3358).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Dermot PB McGovern, MD, PhD,** F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States. dermot.mcgovern@cshs.org

**Telephone:** +1-310-4234100

**Received:** August 5, 2017

**Peer-review started:** August 5, 2017

**First decision:** August 14, 2017

**Revised:** August 25, 2017

**Accepted:** September 13, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To study the type and frequency of adverse events associated with anti-tumor necrosis factor (TNF) therapy and evaluate for any serologic and genetic associations.

***METHODS***

This study was a retrospective review of patients attending the inflammatory bowel disease (IBD) centers at Cedars-Sinai IBD Center from 2005-2016. Adverse events were identified *via* chart review. IBD serologies were measured by ELISA. DNA samples were genotyped at Cedars-Sinai using Illumina Infinium Immunochipv1 array per manufacturer’s protocol. SNPs underwent methodological review and were evaluated using several SNP statistic parameters to ensure optimal allele-calling. Standard and rigorous QC criteria were applied to the genetic data, which was generated using immunochip. Genetic association was assessed by logistic regression after correcting for population structure.

***RESULTS***

Altogether we identified 1258 IBD subjects exposed to anti-TNF agents in whom Immunochip data were available. 269/1258 patients (21%) were found to have adverse events to an anti-TNF-α agent that required the therapy to be discontinued. 25% of women compared to 17% of men experienced an adverse event. All adverse events resolved after discontinuing the anti-TNF agent. In total: *n* = 66 (5%) infusion reactions; *n* = 49 (4%) allergic/serum sickness reactions; *n* = 19 (1.5%) lupus-like reactions, *n* = 28 (2%), *n* = 18 (1.4%) infections. In Crohn’s disease, IgA ASCA (*p* = 0.04) and IgG-ASCA (*p* = 0.02) levels were also lower in patients with any adverse events, and anti-*I*2 level in ulcerative colitis was significantly associated with infusion reactions (*p* = 0.008). The logistic regression/human annotation and network analyses performed on the Immunochip data implicated the following five signaling pathways: JAK-STAT (Janus Kinase-signal transducer and activator of transcription), measles, IBD, cytokine-cytokine receptor interaction, and toxoplasmosis for any adverse event.

***CONLUSION***

Our study shows 1 in 5 IBD patients experience an adverse event to anti-TNF therapy with novel serologic and genetic associations, and pathways analysis.

**Key words:** genetic associations; inflammatory bowel disease; anti-tumor necrosis factor; adverse events

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Tumor necrosis factor-α (TNF-α) plays a key role in the development and progression of inflammatory bowel disease (IBD). Anti-TNF therapy is highly efficacious in treating IBD patients, but many experience adverse events. Few studies have evaluated factors associated with adverse events to anti-TNF therapy. In this study, we found some genetic associations and pathways that are enriched for genes associated with the development of adverse events. Future studies will need to confirm these findings as the ability to identify subjects at high risk may help clinicians anticipate and therefore prevent or avoid these adverse events in the future.

Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D, McGovern DPB.Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients*. World J Gastroenterol* 2017; In press

**Introduction**

Tumor necrosis factor-α (TNF-α) plays a key role in the development and progression of inflammatory bowel disease (IBD)[1-3]. While anti-TNF therapy is an effective therapeutic option for IBD patients[1,4,5], response to these agents is highly heterogeneous and a high proportion of patients either fail initial induction therapy or lose response during maintenance therapy[6-8]. Predicting response to these agents has been studied extensively by evaluating a multitude of factors including potential genetic components[7], but an important addition would be the ability to predict the development of adverse events associated with these agents including: infusion reactions; infections; rash; allergic reactions; serum sickness like reactions; and lupus-like reactions[9-11]. Minimizing the risks is important to increase patient compliance and improve response to therapy, and will also become more important as physicians struggle with decisions around where to position biologic therapies as therapeutics targeting novel mechanisms become available[12,13].

Currently, there are few studies designed to determine factors associated with adverse events to anti-TNF-α therapy. The objectives of this study were to describe the type and frequency of adverse events associated with anti-TNF-α therapy in a large cohort and evaluate for any serologic and genetic associations.

**Materials and methods**

***Study population***

This study was a retrospective review of patients attending the IBD centers at Cedars-Sinai IBD Center from 2005-2016. Patients included in the study were those that had given consent, had available genotype data, carried a diagnosis of IBD (Crohn’s disease, ulcerative colitis, or IBDU), and who had been treated with anti-TNF- α agents (infliximab, adalimumab, certolizumab pegol). All research-related activities were approved by the Cedars-Sinai Medical Center Institutional Review Board (IRB #3358).

***Data gathering***

Detailed clinical information for each patient was obtained via chart review. Clinical information included age at disease diagnosis, type of IBD (CD, UC, or IBDU), gender, and type of anti-TNF-α agent used. All patients were seen by gastroenterologists, experienced in managing patients with IBD treated with anti-TNF agents, at the IBD centers at Cedars-Sinai Medical Center, Los Angeles.

***Adverse events***

Adverse events were identified via chart review by evaluating the “Allergies” section and the progress notes written by the gastroenterologist. Potential adverse events include infusion reactions, serum sickness-like reactions, drug-induced lupus, rash, infections, and non-specific symptoms (arthralgias, shortness of breath, rash, *etc*). An infusion reaction was defined as any significant adverse experience that occurred during or within two hours of infusion[14]. An allergic or a serum sickness-like reaction was defined clinically as the occurrence of myalgias, arthralgias, fever, or rash within 1-14 d after reinfusion of infliximab[15].

The likelihood of a causal relationship for each adverse event was determined based on the assessment of the gastroenterologist as documented in the progress note and as evidenced by the following: time elapsed between a dose and adverse event, resolution of the adverse event when the therapy was discontinued, and return of the adverse event if the therapy was resumed[16].

***Serological analysis***

IBD serologies (ANCA, anti-nuclear cytoplasmic antibodies; anti-CBir1, anti-flagellin; anti-I2, anti-*Pseudomonas fluorescens*-associated sequence I2; anti-OmpC, anti-outer membrane porin C; ASCA, anti-*Saccharomyces cerevisiae* antibodies) were measured by enzyme-linked immunosorbent assay (ELISA) as previously described[17]. Results were expressed as ELISA units (EU/ml) relative to Cedars-Sinai Medical Center laboratory or a Prometheus laboratory standard derived from a pool of patient sera with well-characterized disease found to have reactivity to these antigens. All assays were performed in a blinded fashion.

***Genotype data***

DNA samples were genotyped at Cedars-Sinai using Illumina Infinium Immunochipv1 array per manufacturer’s protocol (Illumina, San Diego, CA, United States). Average genotyping call rate for samples that passed quality control was 99.8%; average replicate concordance and average heritability rates were > 99.99% and 99.94%, respectively. Single-nucleotide polymorphisms (SNPs) underwent methodological review and were evaluated using several SNP statistic parameters to ensure optimal allele-calling[18].

***Statistical analysis***

Chi-square test and logistic regression were performed to identify demographic and clinical characteristics associated with development of adverse events. For continuous variables with skewed distribution (*e.g*., serology levels), Wilcox test signed rank test was performed. SNPs association with adverse events was evaluated using PLINK. Principal components (PCs) from population stratification analysis were included in the PLINK analysis to control for potential confounding[19]. Two-sided *p*-value of 0.05 was considered statistically significant.

***Genetic pathway, and network analyses***

For any reaction, infusion reactions, and allergic reactions, the logistic regression/human annotation and network analysis was performed with statistically significant SNPs (*p* < 0.001). These SNPs were first annotated into corresponding genes, and the genes were further analyzed with multiple biological functional databases including human protein reference databases (www.hprd.org), Reactome, NCI/Nature pathway interaction database and others. The final networks were then constructed form the known interactions from any of these databases. Pathways and gene set enrichment analysis was performed with STRING (http://string-db.org/) and cytoscape (www.cytoscape.org).

**Results**

***Patient demographics and characteristics***

1258 IBD (954 CD patients, 260 UC, 44 IBDU) patients qualified for this study. The average age of onset was 25.7 years and, and the overwhelming majority were of European ancestry.

***Adverse events***

A total of 269/1258 patients (21%) were found to have adverse events to an anti-TNF- α agent that required the therapy to be discontinued (Table 1). All adverse events resolved after discontinuing the anti-TNF agent. In total: 66/1232 (5%) developed infusion reactions; 49/1258 (4%) developed allergic/serum sickness reactions; 19/1258 (1.5%) developed lupus-like reactions; and 83/1258 (7%) developed “other" reactions, which consisted of rash (*n* = 28), infection-related complications (*n* = 18), arthralgias (*n* = 17), shortness of breath (*n* = 13), hives (*n* = 9), headaches (*n* = 4), pancreatitis (*n* = 1), and vasculitis (*n* = 3). Twenty-five percent of women compared to 17% of men experienced an adverse event. The different types of adverse events were similar among women and men, except for lupus-like reactions and rashes, which were both more commonly seen in women (Table 1).

***Serology***

In CD patients we observed that IgA ASCA+/- was associated with a lower risk of developing any adverse event (OR = 0.68, *p* = 0.047), while IgG ASCA+/- and total ASCA+/- show a similar trend and borderline association respectively (OR = 0.72 and 0.70, *p* = 0.09 and 0.05, respectively). IgA ASCA (*p* = 0.04) and IgG ASCA (*p* = 0.02) levels were also lower in patients with any adverse events (Table 2). Anti-I2 level in UC was significantly associated with infusion reactions (*p* = 0.008) (Table 2). No other associations were seen with IBD-associated serologies (data not shown).

***Genetic analysis***

IBD-associated SNPs that achieved a nominal level of significance with adverse events are shown in table 3. For any reaction, infusion reactions, and allergic reactions, the logistic regression/human annotation and network analyses performed on the Immunochip data implicated the following five signaling pathways: JAK-STAT (Janus Kinase-signal transducer and activator of transcription), Measles, IBD, Cytokine-cytokine receptor interaction, and Toxoplasmosis (table 4 and Figure 1). After False Discovery Rate (FDR) correction, all associations remained statistically significant except for the Cytokine-cytokine receptor interaction for infusion and allergic reactions.

**Discussion**

In our cohort approximately 1 in 5 IBD patients experienced adverse events to anti-TNFs that eventually led to the discontinuation of the therapy in keeping with the current literature, although most studies only report the presence or not of adverse events and do not comment on whether patients had to discontinue[20]. The incidence of serious lupus-like reactions requiring the discontinuation of anti-TNFs was found to be 1.1%[21], which was comparable to that seen in our population of 1.5%. To our knowledge, this is the largest study examining adverse events with anti-TNF agents.

We identified a number of genetic associations with known IBD loci including two (*HLA-DRB1* and *ERAP2* [endoplasmic reticulum aminopeptidase 2]) that are associated with a number of immune-mediated diseases as well as IBD and also, in the case of *HLA-DRB1*, with the development of extra-intestinal manifestations in IBD[22-24]. Furthermore, both are involved in peptide presentation by HLA molecules[25,26]. We also observed associations at other IBD genes including *ZNF365,* a transcription factor in maintaining genomic stability during DNA replication in the brain, heart, lung, pancreas, small intestine and colon[27,28]. Our genetic findings also implicated genes that maintain colonic wall permeability including *SPRED* (Sprouty-related EVH1 domain-containing protein) and *PARD3* (Partitioning defective 3 homolog)[29,30]. In addition, *GNA12* (Guanine nucleotide-binding protein alpha-12)*,* amodulator of different transmembrane signaling systems, has also been implicated in the loss of barrier integrity[31]. Our pathway analyses strongly implicated five signaling pathways including JAK-STAT signaling pathway, Cytokine-cytokine receptor interaction pathway, Measles signaling pathway, Toxoplasmosis signaling pathway, and the IBD signaling pathway. The network analyses for allergic reactions (Figure 1) show a number of key nodes including *TYK2, BLK* and *IL13*, which have previously been shown to be associated with allergic susceptibility[32-34].

IBD serologies (ANCA, anti-CBir1, anti-I2, anti-OmpC, and ASCA)can distinguish CD from UC, risk stratify IBD patients, and also predict postoperative complications and occur as a result of an aberrant or exaggerated response to commensal flora[35]. The association with ASCA and I2 are interesting. Perhaps these markers identify patients with a predilection towards small bowel involvement. Patients with colonic disease tend to respond less to anti-TNFs or require higher doses[8,36] and, perhaps therefore, these patients are more likely to develop antibodies or reactions to anti-TNFs. Further studies will be needed to confirm these borderline associations.

There are several potential limitations of this study including, the relatively small sample size and the retrospective nature of the study (despite it being the largest of its kind to date). Additionally, we did not have information on anti-drug antibody formation as the majority of these patients developed adverse events prior to the widespread use of these parameters in clinical practice. It is also important to note that our study population was predominantly of European ancestry. While IBD is rising in non-Europeans, the highest prevalence is still seen in European ancestry populations. For this reason, and the location of Cedars-Sinai Medical Center in west Los Angeles, the majority of our patients are ‘European’. Previous work have shown ethnic differences in genetic associations with adverse events[37], and a study similar to this one should be performed for other ethnic groups.

In conclusion, our study revealed that approximately 1 in 5 IBD patients experienced an adverse event to anti-TNF therapies that required cessation of therapy. The majority of these were infusion/allergic reactions but approximately 1 in 30 women will develop a lupus-like reaction and we also observed other serious adverse events including pancreatitis and vascultitis but these were rare. We have demonstrated some genetic associations and pathways that are enriched for genes associated with development adverse events. Future studies will need to confirm these findings as the ability to identify subjects at high risk may help clinicians anticipate and therefore prevent or avoid these adverse events in the future.

**ARTICLE HIGHLIGHTS**

***Research background***

Tumor necrosis factor (TNF) inhibitors are highly efficacious in treating inflammatory bowel disease (IBD). Response to these agents is highly heterogenous, and there have been a multitude of studies aimed at predicting the response to these agents. An important addition is the ability to predict the development of adverse events associated with these agents such as infusion reactions, infections, or rash. Minimizing the risks is important to increase patient compliance and improve response to therapy.

***Research motivation***

Recognizing the type and frequency of adverse events to anti-TNF therapy, and the potential genetic and serologic associations can help identify subjects at high risk, and may help clinicians anticipate and therefore prevent or avoid these adverse events in the future.

***Research objectives***

The objectives of this study were to describe the type and frequency of adverse events associated with anti-TNF-α therapy in a large cohort and evaluate for any serologic and genetic associations. The significance of realizing these objectives is that it can identify subjects at high risk for developing adverse events and can help clinicians anticipate and therefore prevent or avoid these adverse events in the future.

***Research methods***

This study was a retrospective review, and detailed clinical information was collected *via* manual chart review. Chi-square test and logistic regression were performed to identify demographic and clinical characteristics associated with development of adverse events.

The serological data was measured by ELISA assay at Cedars-Sinai, which was performed in a blinded fashion, and analyzed with Wilcox test signed rank test.

DNA samples were genotyped at Cedars-Sinai using Illumina Infinium Immunochipv1 array per manufacturer’s protocol (Illumina, San Diego, CA, United States). Average genotyping call rate for samples that passed quality control was 99.8%; average replicate concordance and average heritability rates were > 99.99% and 99.94%, respectively. Single-nucleotide polymorphisms (SNPs) underwent methodological review and were evaluated using several SNP statistic parameters to ensure optimal allele-calling. SNPs association with adverse events was evaluated using PLINK, with two-sided p-value of 0.05 was considered statistically significant.

For any reaction, infusion reactions, and allergic reactions, the logistic regression/human annotation and network analysis was performed with statistically significant SNPs (*p* < 0.001). These SNPs were first annotated into corresponding genes, and the genes were further analyzed with multiple biological functional databases. The final networks were then constructed form the known interactions from any of these databases.

The research methods described above are standard for a retrospective review analyzing genetic and serologic data.

***Research results***

About 1 in 5 patients were found to have adverse events to an anti-TNF- α agent that required the therapy to be discontinued. All adverse events resolved after discontinuing the anti-TNF agent. The majority of patients developed infusion reactions. In CD patients we observed that IgA ASCA +/- was associated with a lower risk of developing any adverse event. IgA ASCA and IgG ASCA levels were also lower in patients with any adverse events. Anti-I2 level in UC was significantly associated with infusion reactions. The authors identified a number of genetic associations with known IBD loci including *HLA-DRB1, ERAP2, ZNF365.* Their pathway analyses strongly implicatedJAK-STAT signaling pathway, Cytokine-cytokine receptor interaction pathway, Measles signaling pathway, Toxoplasmosis signaling pathway, and the IBD signaling pathway. The network analyses for allergic reactions showed a number of key nodes including *TYK2, BLK* and *IL13*, which have previously been shown to be associated with allergic susceptibility.

They have demonstrated some novel genetic associations and pathways that are enriched for genes associated with development adverse events. Future studies should be performed to confirm our results, and incorporate other ethnic groups besides European ancestry, and include data on anti-drug antibody formation.

***Research conclusions***

There were genetic and serologic associations found in concordance with adverse events to anti-TNF therapy. This is the first study to evaluate and describe these associations. There are potentially genetic and serologic associations with adverse events to anti-TNF therapy that can help clinicians anticipate and therefore prevent or avoid these adverse events in the future.

Current studies describe in great detail the efficacy of anti-TNF therapy and the ability to predict response to therapy. However, current studies are lacking in evaluating the ability to predict the development of adverse events. The results from this study reveal that there indeed are genetic and serologic associations with anti-TNF therapy that can potentially be targeted to prevent or avoid these adverse events in the future. The new hypothesis proposed by this study is that there are serologic and genetic associations with anti-TNF therapy.

The methods used in this study were similar to other retrospective studies analyzing genetic and serologic data. Manual chart review was performed to gather detailed clinical information; ELISA assay was performed to gather serologic data; and genetic data was gathered using Illumina Infinium Immunochipv1 array. Chi-square test and logistic regression were performed to identify demographic and clinical characteristics associated with development of adverse events; serological data was analyzed with Wilcox test signed rank test; and SNPs association with adverse events was evaluated using PLINK, with two-sided *p*-value of 0.05 was considered statistically significant.

The genetic and serologic associations found in concordance with adverse events to anti-TNF therapy are novel and have not been described elsewhere. This study confirmed that there are genetic and serologic associations with adverse events from anti-TNF therapy. Identifying the potential factors associated with adverse events from anti-TNF therapy can help clinicians anticipate and therefore prevent or avoid these adverse events in the future.

***Research perspectives***

From this study, we are able to learn of novel genetic and serologic associations with anti-TNF therapy. Future research can be directed towards evaluating other ethnic groups and incorporating anti-drug antibody formation. A prospective multi-center study would be the best method of achieving this future study.

**References**

1 **Kontoyiannis D**, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. *Immunity* 1999; **10**: 387-398 [PMID: 10204494 DOI: 10.1016/S1074-7613(00)80038-2]

2 **Neurath MF**, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Büschenfelde KH, Strober W, Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. *Eur J Immunol* 1997; **27**: 1743-1750 [PMID: 9247586 DOI: 10.1002/eji.1830270722]

3 **Targan SR**, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med* 1997; **337**: 1029-1035 [PMID: 9321530 DOI: 10.1056/NEJM199710093371502]

4 **Dignass A**, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 2012; **6**: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]

5 **Rutgeerts P**, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005; **353**: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]

6 **Ordás I**, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2012; **10**: 1079-87; quiz e85-6 [PMID: 22813440 DOI: 10.1016/j.cgh.2012.06.032]

7 **Siegel CA**, Melmed GY. Predicting response to Anti-TNF Agents for the treatment of crohn's disease. *Therap Adv Gastroenterol* 2009; **2**: 245-251 [PMID: 21180547 DOI: 10.1177/1756283X09336364]

8 **Yoon SM**, Haritunians T, Chhina S, Liu Z, Yang S, Landers C, Li D, Ye BD, Shih D, Vasiliauskas EA, Ippoliti A, Rabizadeh S, Targan SR, Melmed GY, McGovern DPB. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. *Inflamm Bowel Dis* 2017; **23**: 1382-1393 [PMID: 28590340 DOI: 10.1097/MIB.0000000000001150]

9 **Colombel JF**, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. *Gastroenterology* 2004; **126**: 19-31 [PMID: 14699483 DOI: 10.1053/j.gastro.2003.10.047]

10 **Antoni C**, Braun J. Side effects of anti-TNF therapy: current knowledge. *Clin Exp Rheumatol* 2002; **20**: S152-S157 [PMID: 12463468]

11 **Scheinfeld N**. Adalimumab: a review of side effects. *Expert Opin Drug Saf* 2005; **4**: 637-641 [PMID: 16011443 DOI: 10.1517/14740338.4.4.637]

12 **Siegel CA**, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. *Clin Gastroenterol Hepatol* 2006; **4**: 1017-24; quiz 976 [PMID: 16843733 DOI: 10.1016/j.cgh.2006.05.020]

13 **Baert F**, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med* 2003; **348**: 601-608 [PMID: 12584368 DOI: 10.1056/NEJMoa020888]

14 Remicade (infliximab) for IV injection. Package insert. Malvern, PA: Centocor Inv., 2002

15 **Kugathasan S**, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, Emmons J, Martinez A, Kelly KJ, Binion DG. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. *Am J Gastroenterol* 2002; **97**: 1408-1414 [PMID: 12094858 DOI: 10.1111/j.1572-0241.2002.05784.x]

16 **Bégaud B**, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. *Therapie* 1985; **40**: 111-118 [PMID: 4002188]

17 **Mow WS**, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. *Gastroenterology* 2004; **126**: 414-424 [PMID: 14762777 DOI: 10.1053/j.gastro.2003.11.015]

18 **Grove ML**, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, Hansen M, Borecki IB, Cupples LA, Fornage M, Gudnason V, Harris TB, Kathiresan S, Kraaij R, Launer LJ, Levy D, Liu Y, Mosley T, Peloso GM, Psaty BM, Rich SS, Rivadeneira F, Siscovick DS, Smith AV, Uitterlinden A, van Duijn CM, Wilson JG, O'Donnell CJ, Rotter JI, Boerwinkle E. Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. *PLoS One* 2013; **8**: e68095 [PMID: 23874508 DOI: 10.1371/journal.pone.0068095]

19 **Purcell S**, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**: 559-575 [PMID: 17701901 DOI: 10.1086/519795]

20 **Lichtenstein L**, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. *J Crohns Colitis* 2015; **9**: 806-815 [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096]

21 **Beigel F**, Schnitzler F, Paul Laubender R, Pfennig S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2011; **17**: 91-98 [PMID: 20564536 DOI: 10.1002/ibd.21362]

22 **Roussomoustakaki M**, Satsangi J, Welsh K, Louis E, Fanning G, Targan S, Landers C, Jewell DP. Genetic markers may predict disease behavior in patients with ulcerative colitis. *Gastroenterology* 1997; **112**: 1845-1853 [PMID: 9178675 DOI: 10.1053/gast.1997.v112.pm9178675]

23 **Ahmad T**, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. *World J Gastroenterol* 2006; **12**: 3628-3635 [PMID: 16773677 DOI: 10.3748/wjg.v12.i23.3628]

24 **Stokkers PC**, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. *Gut* 1999; **45**: 395-401 [PMID: 10446108]

25 **Hulur I**, Gamazon ER, Skol AD, Xicola RM, Llor X, Onel K, Ellis NA, Kupfer SS. Enrichment of inflammatory bowel disease and colorectal cancer risk variants in colon expression quantitative trait loci. *BMC Genomics* 2015; **16**: 138 [PMID: 25766683 DOI: 10.1186/s12864-015-1292-z]

26 **Saveanu L**, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert PM. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. *Nat Immunol* 2005; **6**: 689-697 [PMID: 15908954 DOI: 10.1038/ni1208]

27 **Zhang Y**, Park E, Kim CS, Paik JH. ZNF365 promotes stalled replication forks recovery to maintain genome stability. *Cell Cycle* 2013; **12**: 2817-2828 [PMID: 23966166 DOI: 10.4161/cc.25882]

28 **Haritunians T**, Jones MR, McGovern DP, Shih DQ, Barrett RJ, Derkowski C, Dubinsky MC, Dutridge D, Fleshner PR, Ippoliti A, King L, Leshinsky-Silver E, Levine A, Melmed GY, Mengesha E, Vasilauskas EA, Ziaee S, Rotter JI, Targan SR, Taylor KD. Variants in ZNF365 isoform D are associated with Crohn's disease. *Gut* 2011; **60**: 1060-1067 [PMID: 21257989 DOI: 10.1136/gut.2010.227256]

29 **Takahashi S**, Yoshimura T, Ohkura T, Fujisawa M, Fushimi S, Ito T, Itakura J, Hiraoka S, Okada H, Yamamoto K, Matsukawa A. A Novel Role of Spred2 in the Colonic Epithelial Cell Homeostasis and Inflammation. *Sci Rep* 2016; **6**: 37531 [PMID: 27869219 DOI: 10.1038/srep37531]

30 **Wapenaar MC**, Monsuur AJ, van Bodegraven AA, Weersma RK, Bevova MR, Linskens RK, Howdle P, Holmes G, Mulder CJ, Dijkstra G, van Heel DA, Wijmenga C. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. *Gut* 2008; **57**: 463-467 [PMID: 17989107 DOI: 10.1136/gut.2007.133132]

31 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

32 **Seto Y**, Nakajima H, Suto A, Shimoda K, Saito Y, Nakayama KI, Iwamoto I. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. *J Immunol* 2003; **170**: 1077-1083 [PMID: 12517976 DOI: 10.4049/jimmunol.170.2.1077]

33 **Ashley SE**, Tan HT, Peters R, Allen KJ, Vuillermin P, Dharmage SC, Tang MLK, Koplin J, Lowe A, Ponsonby AL, Molloy J, Matheson MC, Saffery R, Ellis JA, Martino D; HealthNuts team. Genetic variation at the Th2 immune gene IL13 is associated with IgE-mediated paediatric food allergy. *Clin Exp Allergy* 2017; **47**: 1032-1037 [PMID: 28544327 DOI: 10.1111/cea.12942]

34 **Liu Y**, Ke X, Kang HY, Wang XQ, Shen Y, Hong SL. Genetic risk of TNFSF4 and FAM167A-BLK polymorphisms in children with asthma and allergic rhinitis in a Han Chinese population. *J Asthma* 2016; **53**: 567-575 [PMID: 27088737 DOI: 10.3109/02770903.2015.1108437]

35 **Kuna AT**. Serological markers of inflammatory bowel disease. *Biochem Med* (Zagreb) 2013; **23**: 28-42 [PMID: 23457764]

36 **Cohen RD**, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin DT. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. *Inflamm Bowel Dis* 2012; **18**: 10-16 [PMID: 21456032 DOI: 10.1002/ibd.21707]

37 **Yang SK**, Hong M, Baek J, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim KJ, Park SH, Park SK, Yang DH, Dubinsky M, Lee I, McGovern DP, Liu J, Song K. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. *Nat Genet* 2014; **46**: 1017-1020 [PMID: 25108385 DOI: 10.1038/ng.3060]

**P-Reviewer:** Gassler N, Sebastian S, Sergi CM, Zhulina Y **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Adverse events based on type of inflammatory bowel disease and gender**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Clinical traits** | **All adverse events** | **Infusion reactions** | **Allergic reactions** | **Lupus-like reactions** | **Rash** | **Other** |
| Type of IBD |  |  |  |  |  |  |
| Crohn's disease (*n* = 954) | 220 (23) | 52 (5) | 45 (5) | 14 (1) | 40 (4) | 69 (7) |
| Ulcerative colitis (*n* = 260) | 42 (16) | 14 (5) | 4 (2) | 4 (2) | 10 (4) | 10 (4) |
| IBDU (*n* = 44) | 7 (16) | 0 (0) | 0 (0) | 1 (2) | 2 (5) | 4 (9) |
| Total | 269 (21) | 66 (5) | 49 (4) | 19 (1.5) | 52 (4) | 83 (7) |
| Gender |  |  |  |  |  |  |
| Male (*n* = 624) | 108 (17) | 28 (4) | 24 (4) | 3 (0.5) | 17 (3) | 36 (6) |
| Female (*n* = 634) | 161 (25) | 38 (6) | 25 (4) | 16 (3) | 35 (6) | 47 (7) |

All values expressed as *n* (%). IBD: inflammatory bowel disease.

**Table 2 Serological associations with** **anti-tumor necrosis factor adverse reactions in patients with ulcerative colitis and Crohn’s disease (anti-I2, anti-*Pseudomonas fluorescens*-associated sequence I2; ASCA, anti-*Saccharomyces cerevisiae* antibodies)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **IBD type** | **Adverse event** | **Serological marker** | **Serology levels in positive (U/mL)** | **Serology levels in negative (U/mL)** | ***p* value** |
| CD | Any | IgA ASCA | 7 | 10 | 0.04 |
| CD | Any | IgG ASCA | 18 | 26.5 | 0.02 |
| UC | Infusion | Anti-I2 | 0 | 7 | 0.008 |

IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis.

**Table 3 Inflammatory bowel disease-associated single nucleotide polymorphisms associated with different type of adverse events**


|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Adverse event** | **Risk allele** | **SNP** | **Gene (s) of interest** | ***P* value** | **OR (95%CI)** |
| Infusion | C | rs6740462 | *SPRED2* | 0.003 | 0.4 (0.2-0.7) |
| Infusion | G | rs1182188 | *GNA12* | 0.007 | 1.8 (1.2-2.6) |
| Infusion | G | rs10061469 | *TMEM174, FOXD1* | 0.01 | 0.5 (0.3-0.9) |
| Infusion | A | rs477515 | *HLA-DRB1* | 0.01 | 1.7 (1.1-2.5) |
| Allergic | A | rs4692386 | *SMIM20, RBPJ* | 0.01 | 0.5 (0.3-0.9) |
| Allergic | A | rs10761659 | *ZNF365* | 0.01 | 0.6 (0.3-0.9) |
| Lupus-like | G | rs13407913 | *ADCY3* | 0.003 | 3.5 (1.6-7.9) |
| Lupus-like | C | rs10051722 | *CHSY2, HINT1* | 0.01 | 2.7 (1.2-5.7) |
| Rash | A | rs1363907 | *ERAP2* | 0.003 | 3.0 (1.5-6.2) |
| Rash | G | rs11010067 | *PARD3* | 0.003 | 0.2 (0.1-0.6) |
| Rash | C | rs7746082 | *PREP* | 0.005 | 2.7 (1.3-5.3) |
| Any | C | rs6740462 | *SPRED2* | 0.0007 | 0.6 (0.5-0.8) |
| Any | C | rs10774482 | *ERC1* | 0.003 | 1.4 (1.1-1.8) |

SNP: Single nucleotide polymorphisms.

**Table 4 Pathway analyses from genetic associations with adverse events from immunochip analyses**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of adverse event** | **Pathway** | **Number of genes** | ***p* value** | ***p* value (Bonferroni)** |
| Any | JAK-STAT signaling pathway | 13 | 3.98 × 10-6 | 7.96 × 10-4 |
| Any | Measles | 12 | 8.87 × 10-6 | 0.0018 |
| Any | IBD | 8 | 3.05 × 10-5 | 0.0061 |
| Any | Cytokine-cytokine receptor interaction | 16 | 5.03 × 10-5 | 0.01 |
| Any | Toxoplasmosis | 10 | 5.49 × 10-5 | 0.011 |
| Infusion | JAK-STAT signaling pathway | 12 | 3.68 × 10-5 | 0.0074 |
| Infusion | Measles | 12 | 8.24 × 10-6 | 0.0016 |
| Infusion | IBD | 7 | 2.11 × 10-4 | 0.042 |
| Infusion | Cytokine-cytokine receptor interaction | 14 | 4.98 × 10-4 | 0.099 |
| Infusion | Toxoplasmosis | 11 | 9.02 × 10-6 | 0.0018 |
| Allergic | JAK-STAT signaling pathway | 12 | 2.96 ×10-5 | 0.006 |
| Allergic | Measles | 12 | 6.6 × 10-6 | 0.001 |
| Allergic | IBD | 7 | 1.84 × 10-4 | 0.037 |
| Allergic | Cytokine-cytokine receptor interaction | 14 | 4.02 ×10-4 | 0.08 |
| Allergic | Toxoplasmosis | 9 | 2.25 ×10-4 | 0.045 |

IBD: inflammatory bowel disease.

****

**Figure 1 Network analyses of allergic reactions to anti-tumor necrosis factor agents.**